How is industry capacity trending, and what is the outlook for outsourcing? A recent study by BioPlan Associates reveals key ...

The Pharmaceutical Research and Manufacturers of America has filed a complaint that challenges the US government’s MFN drug ...

BD (Becton, Dickinson and Company), a medical technology company, has announced a partnership with the US government under which the company has agreed to invest $19 billion in the ...

AstraZeneca has announced the opening of a new $1-billion global strategic research and development (R&D) center, in Kendall Square, Cambridge, Massachusetts. The center is part of the company’s ...

AstraZeneca has agreed to take a $2-billion equity stake in Summit Therapeutics, a Miami-based bio/pharmaceutical company, and the companies have formed a clinical collaboration to evaluate Summit’s ...

Novo has entered into a license agreement with Hengrui Pharma, a Shanghai-based bio/pharmaceutical company, for HRS-1596, a Phase I-ready glucagon-like peptide-1 receptor (GLP-1R) and gastric ...

Which small-molecule drugs are making the mark in 2026 in new drug approvals or in recently or soon-to-be launched drugs? DCAT Value Chain Insights takes an inside look.

Sanofi has expanded its antibody collaboration with Regeneron Pharmaceuticals, a Tarrytown, New York-based bio/pharmaceutical company, to add four new drug candidates in an $8-billion deal ($1 billion ...

The White House is moving to identify new and unused domestic, US-based, and near-shore production capacity to meet a goal of localizing manufacturing of essential medicines.

The latest from CDMOs, CMOs, and suppliers featuring SK pharmteco, Esteve CDMO, Vetter, Sharp Services, Piramal Pharma Solutions, SPI Pharma, Colorcon, Lonza, and Bespak. Chemicals/Chemical API ...

Roche’s Genentech has broken ground on a $750-million, 211,000-square-foot expansion of its manufacturing facility in Hillsboro, Oregon, to add device fill–finish capabilities, including the ...

What is the state-of-the state for biomanufacturing (drug substance) in terms of industry capacity utilization, in-sourced/outsourced activity, and technology drivers? Is capacity in line with demand ...